Cyclica Drives Drug Discovery Through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer

This post was adapted from its original source on Business Wire and can be viewed here.

TORONTO —(BUSINESS WIRE)— Cyclica (https://www.cyclicarx.com/), a Bayer G4A company, is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies.

Cyclica announces a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies.

Through a multi-phase collaboration, Cyclica will provide its cloud-based proteome screening Ligand Express® platform to investigate the off-target profiles of small molecules, apply its novel and proprietary advanced AI technology to create state-of-the-art predictive models for pharmacokinetic properties, and leverage its first-in-class Differential Drug Design (DDD) technology for multi-targeted drug design.

Naheed Kurji, President and CEO of Cyclica said, “We are thrilled to have the opportunity to work closely with the world-leading scientists at Bayer to advance drug discovery through a holistic set of AI-augmented technologies, and to learn from their experience and expertise to enhance our forthcoming innovation. Securing this collaboration with Bayer, which was catalyzed by our participation in the G4A program, is a testament to Cyclica’s value proposition.”